<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02663219</url>
  </required_header>
  <id_info>
    <org_study_id>HPTN 078</org_study_id>
    <secondary_id>UM1AI068619</secondary_id>
    <secondary_id>11995</secondary_id>
    <nct_id>NCT02663219</nct_id>
  </id_info>
  <brief_title>Enhancing Recruitment, Linkage to Care and Treatment for HIV-Infected MSM in the United States</brief_title>
  <official_title>Enhancing Recruitment, Linkage to Care and Treatment for HIV-Infected Men Who Have Sex With Men (MSM) in the United States</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>HIV Prevention Trials Network</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>HIV Prevention Trials Network</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to develop and assess the efficacy of an integrated strategy&#xD;
      that includes feasible and scalable interventions to identify, recruit, link to care, retain&#xD;
      in care, attain, and maintain viral suppression among HIV-infected men who have sex with men&#xD;
      (MSM) in the United States (US).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will use deep-chain respondent driven sampling (DC-RDS) and direct recruitment&#xD;
      (DR) to identify and recruit HIV-infected MSM who are not virally suppressed. A subset of&#xD;
      these men will be enrolled into one of two study arms. The intervention arm will provide a&#xD;
      Case Manager (CM) intervention package designed to enhance linkage to care, antiretroviral&#xD;
      treatment (ART) initiation, treatment adherence and retention in care. The control arm will&#xD;
      provide the standard of care (SOC) for linkage to care, initiation of ART, treatment&#xD;
      adherence and retention in care. The primary outcome of the study is viral suppression 12&#xD;
      months after enrollment. Phylogenetic methods will be used to evaluate the relationship&#xD;
      between viruses in study participants. Mathematical modeling will be performed using&#xD;
      demographic, behavioral, and clinical data generated from this study and other sources to&#xD;
      estimate the population-level impact of the CM intervention on HIV incidence and to estimate&#xD;
      the level of identification, linkage, ART coverage and viral suppression that would be&#xD;
      required to achieve a substantial reduction in HIV incidence among MSM in the US settings&#xD;
      where the study is conducted.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 6, 2016</start_date>
  <completion_date type="Actual">February 8, 2019</completion_date>
  <primary_completion_date type="Actual">February 8, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>HIV status at screening for each MSM recruited</measure>
    <time_frame>At Baseline</time_frame>
    <description>HIV status</description>
  </primary_outcome>
  <primary_outcome>
    <measure>HIV viral load at screening for each MSM recruited</measure>
    <time_frame>12 months</time_frame>
    <description>HIV viral load</description>
  </primary_outcome>
  <primary_outcome>
    <measure>HIV viral load at month 24 of participants randomized</measure>
    <time_frame>24 months</time_frame>
    <description>time driven HIV viral load</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Date of recruitment for each man recruited by DC-RDS</measure>
    <time_frame>During recruitment period</time_frame>
    <description>recruitment timeline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Wave of recruitment for each man recruited by DC-RDS</measure>
    <time_frame>During recruitment period</time_frame>
    <description>recruitment timeline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HIV viral load of those randomized</measure>
    <time_frame>HIV viral load at Months 3, 6, 9, 12</time_frame>
    <description>HIV viral load</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of all care visits from randomization through the end of 12 months follow up</measure>
    <time_frame>Over 12 months</time_frame>
    <description>clinical care uptake</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time of all care visits from randomization through the end of 12 months follow up</measure>
    <time_frame>Over 12 months</time_frame>
    <description>clinical care uptake</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HCV status at baseline</measure>
    <time_frame>At Baseline</time_frame>
    <description>HCV status</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Baseline Demographics</measure>
    <time_frame>At Baseline</time_frame>
    <description>Participant-administered questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CD4 status at baseline</measure>
    <time_frame>At Baseline</time_frame>
    <description>CD4 cell count</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HIV viral load status at baseline</measure>
    <time_frame>At Baseline</time_frame>
    <description>HIV viral load</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Syphilis status at baseline</measure>
    <time_frame>At Baseline</time_frame>
    <description>Syphilis status</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Self-reported sexual risk behavior of unprotected anal intercourse, characteristics of 3 most recent partners) at baseline and 24 months</measure>
    <time_frame>12 months</time_frame>
    <description>participant-administered questionnaire</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Health care utilization at baseline and 24 months</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>computer assisted self interview</description>
  </other_outcome>
  <other_outcome>
    <measure>Stigma at baseline and 24 months</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>computer assisted self interview</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of contacts (text message, email, phone, in person) for each participant randomized to the CM intervention arm over follow-up</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>clinical contact</description>
  </other_outcome>
  <other_outcome>
    <measure>Open-ended questions for process evaluation</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>Open ended qualitative data compiled and coded</description>
  </other_outcome>
  <other_outcome>
    <measure>The phylogenetic relationship between HIV sequences</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>HIV genetic sequencing</description>
  </other_outcome>
  <other_outcome>
    <measure>Syphilis positive or negative at baseline</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>STI description at baseline</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">144</enrollment>
  <condition>HIV</condition>
  <arm_group>
    <arm_group_label>Intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The intervention arm will provide a Case Manager (CM) intervention package designed to enhance linkage to care, antiretroviral treatment (ART) initiation, treatment adherence and retention in care.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Standard of care</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Intervention</intervention_name>
    <description>The intervention arm will provide a Case Manager (CM) intervention package designed to enhance linkage to care, antiretroviral treatment (ART) initiation, treatment adherence and retention in care.</description>
    <arm_group_label>Intervention</arm_group_label>
    <other_name>Case Management</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Individuals who meet all of the following criteria are eligible for study screening:&#xD;
&#xD;
          -  Biological male (at birth)&#xD;
&#xD;
          -  Self-report of history of anal intercourse with another man&#xD;
&#xD;
          -  16 years or older&#xD;
&#xD;
        Individuals who are eligible for screening and who meet all of the following criteria are&#xD;
        eligible for enrollment into the CM intervention and SOC control arms:&#xD;
&#xD;
          -  HIV-infected, as defined in the HPTN 078 Study-Specific Procedures (SSP) Manual&#xD;
&#xD;
          -  Not virally suppressed (defined as HIV VL ≥ 1000 copies/ml)&#xD;
&#xD;
          -  Can receive HIV care at one of the participating clinics (as chosen by each site)&#xD;
&#xD;
          -  No current plan to relocate in the 24 months following enrollment&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Individuals who meet any of the following criteria will be excluded from study screening:&#xD;
&#xD;
          -  Unable or unwilling to provide consent/assent for study participation.&#xD;
&#xD;
          -  Active or previous participation in an HIV vaccine trial.&#xD;
&#xD;
          -  Any condition that, in the opinion of the Investigator of Record (IoR), would make&#xD;
             participation in the study unsafe, complicate interpretation of study outcome data, or&#xD;
             otherwise interfere with achieving the study objectives.&#xD;
&#xD;
        Individuals who are eligible for screening, but who meet the following criteria are&#xD;
        excluded from enrollment into the CM intervention and SOC control arms:&#xD;
&#xD;
        • Current participation in a linkage or ART adherence study&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <gender_description>biologically male</gender_description>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chris Beyrer, MD/MPH</last_name>
    <role>Study Chair</role>
    <affiliation>Johns Hopkins University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Robert H Remien, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Columbia University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Alabama CRS</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ponce de Leon CRS</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30308-2012</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins Baltimore CRS</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fenway Health CRS</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215-4302</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.hptn.org/sites/default/files/2016-10/R4P_slides_KM_078_modelling_181016_FINAL.pdf</url>
    <description>Potential Impact on HIV Incidence of Increasing Viral Suppression among HIV- positive MSM in Baltimore: Mathematical Modelling for HPTN 078</description>
  </link>
  <reference>
    <citation>KM Mitchell, B Hoots, D Dimitrov, et al. Potential Impact on HIV Incidence of Increasing Viral Suppression among HIV- positive MSM in Baltimore: Mathematical Modelling for HPTN 078. HIV Research for Prevention (HIVR4P 2016). Chicago, October 17-21, 2016. Abstract OA10.04</citation>
  </reference>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>January 13, 2016</study_first_submitted>
  <study_first_submitted_qc>January 21, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 26, 2016</study_first_posted>
  <last_update_submitted>October 29, 2021</last_update_submitted>
  <last_update_submitted_qc>October 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>MSM</keyword>
  <keyword>ART</keyword>
  <keyword>CCM</keyword>
  <keyword>DAIDS</keyword>
  <keyword>HPTN</keyword>
  <keyword>ACA</keyword>
  <keyword>PAF</keyword>
  <keyword>PEP</keyword>
  <keyword>RDS</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

